CDXS News and Press, Codexis Inc. From 02/23/23

Codexis press release ( NASDAQ: CDXS ): Q4 GAAP EPS of $0.19 beats by $0.42 . Revenue of $30.4M (+24.1% Y/Y) beats by $1.48M . Total revenues are expected to be in the range of $63 million to $68 million, vs. consensus of $91.98M. For further details see: ...

Biotherapeutics Application of CodeEvolver ® Validated by Recent Data Supporting the Potential for Three Upcoming Investigational New Drug Applications Cash Runway Through End of 2024 Funds Important Upcoming Milestones Company Provides 2023 Revenue Guidance REDWO...

REDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, and Nestlé Health Science, a leader in the science of nutrition, today announced interim results from a Phase 1 study to investigate the safety, tolerability, pharmacok...

REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today highlights several key presentations from its gene therapy programs from 19 th Annual WORLD Symposium ™ , taking place from February 22-26, ...

REDWOOD CITY, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the grant of an inducement award to the Company’s recently appointed Chief Financial Officer, Sri Ryali. As previously announced, Mr. Ryali joined the...

REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2022 on Thursday, February 23, 2023, following the close of market. Codexis ...

Summary Codexis continues to face downside pressure from investors as we roll through the new year. Despite announcing two potential price catalysts, the market's price response was mute, indicating more is required for a reversal. The company has affirmed FY22 guidance last year an...

Summary Baillie Gifford’s 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. They increased NVIDIA, Shopify, NIO Inc., SEA Ltd., Roblox, DoorDash, and Ginkgo Bioworks while reducing Illumina, Ferrari N.V., Arthur J. Gallagher & Co., Albemarle, Meta Platform...

Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...

Enzyme engineering company Codexis ( NASDAQ: CDXS ) on Monday said it had appointed Sri Ryali as CFO, effective immediately. The company said Ryali had most recently served as the CFO of Eiger BioPharmaceuticals ( EIGR ). Ryali also held positions in companies su...